FDA Announces Public Meeting on Dietary Supplement Innovation and Ingredient Scope

FDA to Hold Public Meeting on Dietary Supplement Innovation and Ingredient Scope

The U.S. Food and Drug Administration has announced an upcoming public meeting focused on dietary supplement innovation and the scope of dietary ingredients under the Dietary Supplement Health and Education Act (DSHEA).

The announcement was issued by FDA’s Human Foods Program, the office responsible for oversight of both conventional foods and dietary supplements following the Agency’s recent organizational restructuring.

The meeting will provide a forum for FDA, industry stakeholders, and other interested parties to discuss how dietary ingredient definitions and regulatory frameworks may impact innovation within the dietary supplement market.

Meeting Focus

• The scope of ingredients that may qualify as dietary ingredients
• Scientific and regulatory considerations for new ingredients
• Opportunities and challenges associated with innovation in the dietary supplement industry
• Stakeholder perspectives on current regulatory approaches

Background

Dietary supplements are regulated under the Dietary Supplement Health and Education Act of 1994 (DSHEA). The law defines dietary ingredients and establishes requirements related to safety, labeling, and marketing.

Over time, evolving ingredient technologies and product formulations have raised questions about how certain substances may fit within existing statutory definitions.

Why This Matters

The public meeting may provide insight into how FDA views the boundaries of dietary ingredient eligibility and how regulatory policy may evolve as the market continues to innovate.

The involvement of the Human Foods Program reflects FDA’s broader effort to evaluate ingredient oversight across both conventional foods and dietary supplements.

EAS Perspective

Public meetings such as this allow FDA to gather input from stakeholders and better understand how regulatory frameworks influence innovation in the dietary supplement sector.

Companies developing new ingredients or novel formulations may wish to monitor these discussions and consider participating in the meeting.

EAS will continue tracking developments related to dietary supplement policy and provide updates as new information becomes available.